Biocryst Pharmaceuticals (BCRX) Asset Writedowns and Impairment (2023 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Asset Writedowns and Impairment of $74000.0 for Q1 2026, up 107.01% on a QoQ basis from -$1.1 million in Q4 2025, and down 64.59% year-over-year from $209000.0 in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Asset Writedowns and Impairment (2023 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $74000.0 for Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 64.59% year-over-year to $74000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$135000.0 (down 108.66% YoY) and the FY2024 annual result came in at $1.3 million, down 12.79% from the prior year.
- Asset Writedowns and Impairment was $74000.0 for Q1 2026 at Biocryst Pharmaceuticals, up from -$1.1 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.4 million in Q3 2024 and bottomed at -$1.1 million in Q4 2025.
- A 4-year average of $247666.7 and a median of $52000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
- Peak annual rise in Asset Writedowns and Impairment reached 81600.0% in 2025, while the deepest fall reached 9500.0% in 2025.
- Biocryst Pharmaceuticals' Asset Writedowns and Impairment stood at $1.3 million in 2023, then tumbled by 100.84% to -$11000.0 in 2024, then sank by 9500.0% to -$1.1 million in 2025, then soared by 107.01% to $74000.0 in 2026.
- Business Quant data shows BCRX's Asset Writedowns and Impairment at $74000.0 in Q1 2026, -$1.1 million in Q4 2025, and $30000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.35 Bn | 2.28 Bn | 151.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | -1.06 Mn |
| Dec 31, 2025 | -1.06 Mn |
| Sep 30, 2025 | 30,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 817,000.00 |
| Jun 30, 2025 | 817,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Dec 31, 2024 | -11,000.00 |
| Dec 31, 2024 | -11,000.00 |
| Sep 30, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Dec 31, 2023 | 1.31 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Sep 30, 2023 | -2,000.00 |
| Sep 30, 2023 | -2,000.00 |